Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06611774

Metabolic Syndrome in Patients with Knee Osteoarthritis

Status
Not Yet Recruiting
Phase
Study type
Observational
Enrollment
174 (estimated)
Sponsor
Assiut University · Academic / Other
Sex
All
Age
30 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Study the prevalence of metabolic syndrome in patients with knee osteoarthritis and conclude the relationship between metabolic syndrome and the severity of knee osteoarthritis

Detailed description

Osteoarthritis is one of the most common clinical conditions causing severe chronic and restrictive disability, especially in elderly people. Of those aged 60 years and older, 10% of men and 13% of women had symptomatic knee OA . As the population ages and the prevalence of obesity and overweight generaly rises , the percentage of persons affected with symptomatic knee OA will likely increase. The clinical manifestations in patients are joint pain, stiffness, and functional limitation . Among all body joints; knee joint is the most commonly affected joint with osteoarthritis and accounts almost for four-fifth of the osteoarthritis burden worldwide . Epidemiological research has shown an encouraging relationship between OA and metabolic syndrome , MetS include hypertension, dyslipidemia, hyperglycemia, and obesity .Recently, metabolic OA has been nominated as the fifth component of MetS . Studies reported that adipokines may contribute to the development of osteoarthritis (OA) by increasing inflammatory cytokines and growth factors, modifying insulin sensitivity, and triggering processes that break down cartilage. Studies also reported that hypertension can be linked to osteoarthritis through astherosclerosis which cause subchondral bone ischemia accelerating OA progression. Furthermore, researches have linked glucose levels to knee osteoarthritis , supporting the possibility of pathophysiological mechanisms such oxidative stress in the chondrocytes and Cartilage-associated production of advanced glycation end products (AGEs) .

Conditions

Timeline

Start date
2024-10-01
Primary completion
2026-11-01
Completion
2027-02-01
First posted
2024-09-25
Last updated
2024-09-25

Source: ClinicalTrials.gov record NCT06611774. Inclusion in this directory is not an endorsement.